Carbaglu

RSS

carglumic acid

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Carbaglu. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Carbaglu.

This EPAR was last updated on 09/06/2021

Authorisation details

Product details
Name
Carbaglu
Agency product number
EMEA/H/C/000461
Active substance
carglumic acid
International non-proprietary name (INN) or common name
carglumic acid
Therapeutic area (MeSH)
  • Amino Acid Metabolism, Inborn Errors
  • Propionic Acidemia
Anatomical therapeutic chemical (ATC) code
A16AA05
Publication details
Marketing-authorisation holder
Recordati Rare Diseases
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
24/01/2003
Contact address

Immeuble le Wilson
70, avenue du Général de Gaulle
92800 Puteaux
France

Product information

16/05/2019 Carbaglu - EMEA/H/C/000461 - IG/1085/G

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Carbaglu is indicated in treatment of:

  • hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;
  • hyperammonaemia due to isovaleric acidaemia;
  • hyperammonaemia due to methymalonic acidaemia;
  • hyperammonaemia due to propionic acidaemia.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating